Find Funding Opportunities

The National Institute on Aging (NIA), National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Nursing Research (NINR) are continuing joint sponsorship of a predoctoral research training program in the neurosciences. The aim of the program is to encourage and support broad, early-stage (pre-thesis) training in the neurosciences by offering institutions a single comprehensive training grant. It is expected that these training programs will contribute to basic and disease-related neuroscience research that is relevant to the participating NIH Institutes.

Participating Institutes and Centers (ICs) of the National Institutes of Health (NIH) invite applications for R01 awards to support Bioengineering Research Grants (BRGs) for basic and applied multi-disciplinary research that addresses important biological or medical research problems. The BRGs support multi- disciplinary research performed in a single laboratory or by a small number of investigators that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research at universities, national laboratories, medical schools, large or small businesses, or other public and private entities.

Participating Institutes and Centers (ICs) of the National Institutes of Health (NIH) invite applications for R01 awards to support Bioengineering Research Partnerships (BRPs) for basic and applied multi-disciplinary research that addresses important biological or medical research problems. A BRP is a multi- disciplinary research team applying an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. The partnership must include appropriate bioengineering or allied quantitative sciences in combination with biomedical and/or clinical investigators. A BRP may propose hypothesis-driven, discovery- driven, developmental, or design-directed research at universities, national laboratories, medical schools, large or small businesses, or other public and private entities or combinations of these entities.

The National Institute of Neurological Disorders and Stroke (NINDS) invites grant applications for the formation of cross-disciplinary networks of scientists interested in studying the neural mechanisms of cognition and other complex behaviors. These research networks will allow the formation of novel collaborations among cognitive scientists, neuroscientists, behavioral and computational neuroscientists, imaging specialists and clinical scientists in order to develop integrative and cutting edge research programs that advance our understanding of the circuits and pathways of cognitive function. The research plan for these networks must be driven by a cognitive neuroscience question (e.g., neural mechanisms of attention, emotion, language acquisition, memory, perception, sensorimotor integration in various model systems and in various clinical populations) and must combine imaging techniques with other psychophysiological methods. This RFA is intended to begin a process where scientists from various disciplines can overcome barriers to cross-disciplinary research agendas addressing the dynamic nature of underlying physiological and cognitive systems.

This RFA supports novel basic research designed to elucidate effects of whole-body ischemia and subsequent blood flow restoration on cardiovascular and neurological function. The ultimate goal is to provide a rational basis for development of effective new therapeutic strategies to restore heart function and preserve neurological function after cardiopulmonary arrest.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Dental and Craniofacial Research (NIDCR) encourage investigator-initiated research grant applications on pathogenesis and treatment of inflammatory myopathy. Responses to this program announcement may include studies in appropriate animal models or preclinical or clinical studies in patients with any form of inflammatory muscle disease.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Eye Institute (NEI) and the National Institute of Neurological Disorders and Stroke (NINDS) seek applications to develop and validate biomarkers for the microvascular complications of diabetes. Prevention and treatment of long-term micro- and macrovascular complications remain a critical problem in the management of type 1 and type 2 diabetes mellitus. In the United States, diabetes is the leading cause of new blindness in working-age adults, of new cases of end stage renal disease and of non-traumatic lower leg amputations. Basic science advances in the coming years are expected to lead to new therapies to prevent or treat the development of nephropathy, retinopathy and neuropathy. Surrogate endpoints for complications can be utilized in clinical trials to assess the efficacy of these new therapies. In addition, such biomarkers may be useful for predicting those patients who are at high risk for the development of complications, and who may benefit from aggressive intervention.

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Juvenile Diabetes Research Foundation (JDRF) solicit applications for studies designed to elucidate the effects of acute and recurrent episodes of hypoglycemia on glial and neuronal cells of the developing and mature central nervous system. Recent therapeutic strategies aimed at closely controlling elevated glucose levels in diabetic individuals put them at risk for experiencing episodes of hypoglycemia. Acute and recurrent hypoglycemia may cause transient or persistent alteration of cognitive function, and can result in seizures or coma. Recent studies of ischemia have provided information about the effects of glucose deprivation coupled with hypoxia on cells of the central nervous system. However, less is known about the effects of reduced glycemic levels on CNS cell function and survival in a normoxic environment.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD), the National Institute of Nursing Research (NINR) and the Juvenile Diabetes Research Foundation International (JDRF) solicit applications for clinical studies designed to enhance understanding and prevention of hypoglycemia in patients with diabetes. Large clinical trials have demonstrated the efficacy of intensified glucose control in the prevention of the long-term complications of diabetes. However, episodes of severe hypoglycemia may complicate intensified treatment and are often a major obstacle to the achievement of euglycemia in many patients. This RFA solicits clinical studies to 1) define and characterize hypoglycemia in diabetic individuals and 2) develop new approaches to prevent the development of hypoglycemia or to ameliorate its effects in individuals with diabetes.

Deep brain stimulation (DBS) in the thalamus for the treatment of tremor was approved by the FDA in 1997 following the pioneering work of Benabid and colleagues in France. Subsequently it has been found that stimulation in the subthalamic nucleus (STN) or globus pallidus (GPi) can relieve multiple symptoms of Parkinson"s disease (PD). DBS has been successful in restoring significant mobility to a large number of patients with advanced PD. During the past year, GPi and STN stimulation underwent review at the FDA for potential use to decrease symptoms of dyskinesia, tremor, postural instability, and/or bradykinesia in individuals with advanced PD.